Ibandronate

Generic name: Pronounced as (i ban' droh nate)
Brand names
  • Boniva®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2016

Ibandronate is used to prevent and treat osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life,'' end of menstrual periods). Ibandronate is in a class of medications called bisphosphonates. It works by preventing bone breakdown and increasing bone density (thickness).

Ibandronate comes as a tablet to take by mouth. The 2.5-mg tablet is usually taken once a day in the morning on an empty stomach and the 150-mg tablet is usually taken once a month in the morning on an empty stomach. The 150-mg tablet should be taken on the same date each month. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take ibandronate exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Ibandronate may not work properly and may damage the esophagus (tube between the mouth and stomach) or cause sores in the mouth if it is not taken according to the following instructions. Tell your doctor if you do not understand, you do not think you will remember, or you are unable to follow these instructions:

  • You must take ibandronate just after you get out of bed in the morning, before you eat or drink anything. Never take ibandronate at bedtime or before you wake up and get out of bed for the day.

  • Swallow the tablets with a full glass (6 to 8 ounces [180 to 240 mL]) of plain water. Never take ibandronate with tea, coffee, juice, milk, mineral water, sparkling water, or any liquid other than plain water.

  • Swallow the tablets whole; do not split, chew, or crush them. Do not suck on the tablets.

  • After you take ibandronate, do not eat, drink, or take any other medications (including vitamins or antacids) for at least 60 minutes. Do not lie down for at least 60 minutes after you take ibandronate. Sit upright or stand upright for at least 60 minutes.

Ibandronate controls osteoporosis but does not cure it. Ibandronate helps to treat and prevent osteoporosis only as long as it is taken regularly. Continue to take ibandronate even if you feel well. Do not stop taking ibandronate without talking to your doctor, but talk to your doctor from time to time about whether you still need to take ibandronate.

Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with ibandronate and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking ibandronate,

  • tell your doctor and pharmacist if you are allergic to ibandronate, any other medications, or any of the ingredients in ibandronate tablets. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: angiogenesis inhibitors such as bevacizumab (Avastin), everolimus (Afinitor, Zortress), pazopanib (Votrient), sorafenib (Nexavar), or sunitinib (Sutent); aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Ibu-Tab, Motrin, others) and naproxen (Aleve, Naprelan, Naprosyn, others); cancer chemotherapy; and oral steroids such as dexamethasone, methylprednisolone (Medrol), and prednisone (Rayos). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • if you are taking any oral medications, including supplements, vitamins, or antacids, take them at least 60 minutes after you take ibandronate.

  • tell your doctor if you are unable to sit upright or stand upright for at least 60 minutes and if you have or have ever had a low level of calcium in your blood. Your doctor may tell you not to take ibandronate.

  • tell your doctor if are undergoing radiation therapy and if you have or have ever had anemia (condition in which the red blood cells do not bring enough oxygen to all the parts of the body); difficulty swallowing; heartburn; ulcers or other problems with your stomach or esophagus (tube that connects the throat to the stomach); cancer; any type of infection, especially in your mouth; problems with your mouth, teeth, or gums; any condition that stops your blood from clotting normally; or kidney disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Also tell your doctor if you plan to become pregnant at any time in the future, because ibandronate may remain in your body for years after you stop taking it. Call your doctor if you become pregnant during or after your treatment.

  • you should know that ibandronate may cause osteonecrosis of the jaw (ONJ, a serious condition of the jaw bone), especially if you have dental surgery or treatment while you are taking the medication. A dentist should examine your teeth and perform any needed treatments, including cleaning or fixing ill-fitted dentures, before you start to take ibandronate. Be sure to brush your teeth and clean your mouth properly while you are taking ibandronate. Talk to your doctor before having any dental treatments while you are taking this medication.

  • you should know that ibandronate may cause severe bone, muscle, or joint pain. You may begin to feel this pain within days, months, or years after you first take ibandronate. Although this type of pain may begin after you have taken ibandronate for some time, it is important for you and your doctor to realize that it may be caused by ibandronate. Call your doctor right away if you experience severe pain at any time during your treatment with ibandronate. Your doctor may tell you to stop taking ibandronate and your pain may go away after you stop taking the medication.

  • talk to your doctor about other things you can do to prevent osteoporosis from developing or worsening. Your doctor will probably tell you to avoid smoking and drinking large amounts of alcohol and to follow a regular program of weight-bearing exercise.

You should eat and drink plenty of foods and drinks that are rich in calcium and vitamin D while you are taking ibandronate. Your doctor will tell you which foods and drinks are good sources of these nutrients and how many servings you need each day. If you find it difficult to eat enough of these foods, tell your doctor. In that case, your doctor may prescribe or recommend a supplement.

If you forget to take the daily 2.5-mg tablet, do not take it later in the day. Skip the missed dose and continue your regular dosing schedule the next morning. Do not take two tablets of ibandronate on the same day.

If you forget to take the once-monthly 150-mg tablet, and your next scheduled day to take ibandronate is more than 7 days away, take one tablet the morning after you remember. Then return to taking one tablet each month on the regularly scheduled date. If you forget to take the once-monthly 150-mg tablet and your next scheduled day to take ibandronate is 7 or fewer days away, skip the dose and wait for your next scheduled day. You should not take two 150-mg tablets of ibandronate within 1 week.

If you are not sure what to do if you miss a dose of ibandronate, call your doctor.

  • Ibandronate may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • nausea

    • stomach pain

    • diarrhea

    • constipation

    • weakness

    • dizziness

    • headache

    • fever, sore throat, chills, cough, and other signs of infection

    • frequent or urgent need to urinate

    • painful urination

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately before you take any more ibandronate:

    • new or worsening heartburn

    • difficulty swallowing

    • pain on swallowing

    • upper chest pain

    • rash

    • painful or swollen gums

    • loosening of the teeth

    • numbness or heavy feeling in the jaw

    • poor healing of the jaw

    • dull, aching pain in the hips, groin, or thighs

  • Ibandronate may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • Taking a bisphosphonate medication such as ibandronate for osteoporosis may increase the risk that you will break your thigh bone(s). You may feel pain in your hips, groin, or thighs for several weeks or months before the bone(s) break, and you may find that one or both of your thigh bones have broken even though you have not fallen or experienced other trauma. It is unusual for the thigh bone to break in healthy people, but people who have osteoporosis may break this bone even if they do not take ibandronate. Talk to your doctor about the risks of taking ibandronate.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, give the victim a full glass of milk and call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911. Do not allow the victim to lie down and do not try to make the victim vomit.

Symptoms of overdose may include the following:

  • nausea

  • stomach pain

  • heartburn

Keep all appointments with your doctor. Your doctor may order certain tests to check your body's response to ibandronate.

Before having any bone imaging study, tell your doctor and healthcare personnel that you are taking ibandronate.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.
Montelukast Montelukast The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Ibandronate.
Leflunomide Leflunomide The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Leflunomide.
Atorvastatin Atorvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Atorvastatin.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dolasetron.
Alendronate Alendronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Anagrelide.
Calcium Carbonate Calcium Carbonate The serum concentration of Ibandronate can be decreased when it is combined with Calcium carbonate.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cilostazol.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erythromycin.
Fenofibrate Fenofibrate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fenofibrate.
Magnesium Gluconate Magnesium Gluconate Magnesium gluconate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium Hydroxide Magnesium Hydroxide The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.
Magnesium Oxide Magnesium Oxide The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
Nafarelin Nafarelin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Ibandronate.
Olsalazine Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Olsalazine is combined with Ibandronate.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acebutolol.
Ranitidine Ranitidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ranitidine.
Tacrolimus Tacrolimus The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Ibandronate.
Tiludronate Tiludronate The risk or severity of adverse effects can be increased when Ibandronate is combined with Etidronic acid.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Ibandronate.
Triamcinolone Triamcinolone The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Ibandronate.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Famotidine.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Ibandronate.
Foscarnet Injection Foscarnet Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Ibandronate.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin.
Metoclopramide Injection Metoclopramide Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Metronidazole.
Pamidronate Injection Pamidronate Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Ibandronate.
Vancomycin Injection Vancomycin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Ibandronate.
Zidovudine Injection Zidovudine Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Ibandronate.
Cefuroxime Cefuroxime The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Ibandronate.
Cyclosporine Cyclosporine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Ibandronate.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ondansetron.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Granisetron.
Torsemide Torsemide The risk or severity of hypocalcemia can be increased when Torasemide is combined with Ibandronate.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Ibandronate.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dofetilide.
Eprosartan Eprosartan The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Eprosartan.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Hydroxychloroquine.
Meloxicam Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Meloxicam is combined with Ibandronate.
Pantoprazole Pantoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.
Risedronate Risedronate The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Risedronic acid.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desloratadine.
Trimipramine Trimipramine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Trimipramine.
Tenofovir Tenofovir The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir is combined with Ibandronate.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Ibandronate.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Zonisamide.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Ibandronate.
Atazanavir Atazanavir The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Ibandronate.
Mefloquine Mefloquine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Ibandronate.
Rosuvastatin Rosuvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Rosuvastatin.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vardenafil.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Ibandronate.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Apomorphine.
Infliximab Injection Infliximab Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Ibandronate.
Protriptyline Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Ibandronate.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erlotinib.
Ganciclovir Ganciclovir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Ganciclovir.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Solifenacin.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Ibandronate.
Zoledronic Acid Injection Zoledronic Acid Injection The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.
Adefovir Adefovir The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir is combined with Ibandronate.
Pregabalin Pregabalin The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Ibandronate.
Deferasirox Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Ibandronate is combined with Deferasirox.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felbamate.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ranolazine.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imatinib.
Bevacizumab Injection Bevacizumab Injection The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Ibandronate.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salbutamol.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ibandronate.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Oxaliplatin.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Posaconazole.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Primaquine.
Ranibizumab Injection Ranibizumab Injection The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dimenhydrinate.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vorinostat.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Ibandronate.
Sunitinib Sunitinib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Ibandronate.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lapatinib.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levocetirizine.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dasatinib.
Ivermectin Ivermectin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Ibandronate.
Lenalidomide Lenalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Ibandronate.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Toremifene.
Raltegravir Raltegravir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Raltegravir.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Arsenic trioxide.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flecainide.
Daptomycin Injection Daptomycin Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Ibandronate.
Naltrexone Injection Naltrexone Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Ibandronate.
Dexlansoprazole Dexlansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Dexlansoprazole.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Degarelix.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Iloperidone.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dronedarone.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Romidepsin.
Pazopanib Pazopanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Ibandronate.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Asenapine.
Pitavastatin Pitavastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Pitavastatin.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin.
Ceftaroline Injection Ceftaroline Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Ibandronate.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lurasidone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Terbutaline.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Rilpivirine.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triptorelin.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vandetanib.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Vemurafenib.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Crizotinib.
Iloprost Iloprost The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Iloprost.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Mirabegron.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bedaquiline.
Pomalidomide Pomalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Ibandronate.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Dabrafenib.
Ketorolac Injection Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Ibandronate.
Iron Sucrose Injection Iron Sucrose Injection Iron sucrose can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ceritinib.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Risperidone.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Haloperidol.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivabradine.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ziprasidone.
Trabectedin Injection Trabectedin Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Trabectedin.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.
Dexamethasone Injection Dexamethasone Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Dexamethasone.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diphenhydramine.
Furosemide Injection Furosemide Injection The risk or severity of hypocalcemia can be increased when Furosemide is combined with Ibandronate.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ribociclib.
Parathyroid Hormone Injection Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibandronate.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Doxepin.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Deutetrabenazine.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Delafloxacin.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tetrabenazine.
Penicillamine Penicillamine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Penicillamine.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Lofexidine.
Plazomicin Injection Plazomicin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Ibandronate.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ivosidenib.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Glasdegib.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Paclitaxel.
Magnesium Citrate Magnesium Citrate Magnesium citrate can cause a decrease in the absorption of Ibandronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acyclovir Ophthalmic Acyclovir Ophthalmic The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Ibandronate.
Esomeprazole Injection Esomeprazole Injection The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.
Cladribine Cladribine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Ibandronate.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Triclabendazole.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Entrectinib.
Pitolisant Pitolisant Ibandronate may increase the QTc-prolonging activities of Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Ibandronate.
Phenytoin Injection Phenytoin Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Ibandronate.
Brolucizumab-dbll Injection Brolucizumab-dbll Injection The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Ibandronate.
Calcium Acetate Calcium Acetate The serum concentration of Ibandronate can be decreased when it is combined with Calcium acetate.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fostemsavir.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Ibandronate.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Relugolix.
Tobramycin Injection Tobramycin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Ibandronate.
Fenoprofen Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Ibandronate.
Indomethacin Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Ibandronate.
Mefenamic Acid Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Ibandronate.
Naproxen Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Ibandronate.
Tolmetin Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Ibandronate.
Sulindac Sulindac The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Ibandronate.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Ibandronate.
Isotretinoin Isotretinoin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Isotretinoin.
Sodium Bicarbonate Sodium Bicarbonate The serum concentration of Ibandronate can be decreased when it is combined with Sodium bicarbonate.
Methotrexate Injection Methotrexate Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Ibandronate.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methsuximide.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpromazine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amantadine.
Procarbazine Procarbazine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Procarbazine.
Minocycline Minocycline The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Minocycline.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Prochlorperazine.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thioridazine.
Methadone Methadone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methadone.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ibandronate.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline.
Ibuprofen Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Ibandronate.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Orphenadrine.
Amoxapine Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Ibandronate.
Sulfasalazine Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate.
Cytarabine Cytarabine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Cytarabine.
Phenazopyridine Phenazopyridine The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Ibandronate.
Methyldopa Methyldopa The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Methyldopa.
Cimetidine Cimetidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Ibandronate.
Gentamicin Injection Gentamicin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Ibandronate.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Loperamide.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Promethazine.
Meclofenamate Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Ibandronate.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ibandronate.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chloroquine.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Ibandronate.
Triamterene Triamterene The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Ibandronate.
Desipramine Desipramine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desipramine.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amitriptyline.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imipramine.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Procainamide.
Isoniazid Isoniazid The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Isoniazid.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Ibandronate.
Propylthiouracil Propylthiouracil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Ibandronate.
Niacin Niacin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Ibandronate.
Baclofen Baclofen The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Ibandronate.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ibandronate.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Ibandronate.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ibandronate.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Ibandronate.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disulfiram.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propranolol.
Nortriptyline Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Ibandronate.
Amphotericin B Injection Amphotericin B Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Ibandronate.
Amikacin Injection Amikacin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Ibandronate.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Ibandronate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Fluorouracil.
Colchicine Colchicine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Colchicine.
Cefaclor Cefaclor The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Ibandronate.
Cefadroxil Cefadroxil The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Ibandronate.
Cefazolin Injection Cefazolin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Ibandronate.
Cephalexin Cephalexin The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Ibandronate.
Cefoxitin Injection Cefoxitin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Ibandronate.
Cefotaxime Injection Cefotaxime Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Ibandronate.
Calcitonin Salmon Injection Calcitonin Salmon Injection The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Ibandronate.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ketoconazole.
Vincristine Injection Vincristine Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Ibandronate.
Captopril Captopril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Captopril.
Ethacrynic Acid Ethacrynic Acid The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Ibandronate.
Colistimethate Injection Colistimethate Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistimethate is combined with Ibandronate.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ibandronate.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thiothixene.
Aspirin Aspirin The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.
Salsalate Salsalate The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Ibandronate.
Triazolam Triazolam The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Triazolam.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Ibandronate.
Trimethoprim Trimethoprim The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Ibandronate.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Diltiazem.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Ibandronate.
Cisplatin Injection Cisplatin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate.
Diflunisal Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Ibandronate.
Piroxicam Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Ibandronate.
Bumetanide Bumetanide The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Ibandronate.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Indapamide.
Pentamidine Injection Pentamidine Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pentamidine is combined with Ibandronate.
Ceftriaxone Injection Ceftriaxone Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Ibandronate.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Leuprolide.
Gemfibrozil Gemfibrozil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Gemfibrozil.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Ibandronate.
Ceftazidime Injection Ceftazidime Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Ibandronate.
Ketoprofen Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Ibandronate.
Cefotetan Injection Cefotetan Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Ibandronate.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Pimozide.
Enalapril Enalapril The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Ibandronate.
Flurbiprofen Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Ibandronate.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Amiodarone.
Lovastatin Lovastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Ibandronate.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate.
Diclofenac Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Ibandronate.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Ibandronate.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Nimodipine.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clozapine.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clarithromycin.
Etodolac Etodolac The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Ibandronate.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Felodipine.
Nabumetone Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Ibandronate.
Pravastatin Pravastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Ibandronate.
Simvastatin Simvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Ibandronate.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Itraconazole.
Oxaprozin Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Ibandronate.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sotalol.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Ibandronate.
Omeprazole Omeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Cisapride.
Fluvastatin Fluvastatin The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Fluvastatin.
Venlafaxine Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ibandronate.
Nizatidine Nizatidine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Ibandronate.
Stavudine Stavudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Ibandronate.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Ibandronate.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Ibandronate.
Valacyclovir Valacyclovir The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Ibandronate.
Carboplatin Injection Carboplatin Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Ibandronate.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Ibandronate.
Lansoprazole Lansoprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.
Nicardipine Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ibandronate.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Saquinavir.
Lamivudine Lamivudine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Ibandronate.
Indinavir Indinavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Ibandronate.
Ritonavir Ritonavir The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Ibandronate.
Docetaxel Injection Docetaxel Injection The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Docetaxel.
Cidofovir Injection Cidofovir Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Ibandronate.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Clomipramine.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Ibandronate.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ibandronate.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Azithromycin.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Propafenone.
Letrozole Letrozole The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Letrozole.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Quetiapine.
Cefepime Injection Cefepime Injection The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Ibandronate.
Cefprozil Cefprozil The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Ibandronate.
Cefpodoxime Cefpodoxime The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Ibandronate.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ibandronate.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Citalopram.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Efavirenz.
Sildenafil Sildenafil The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Ibandronate.
Celecoxib Celecoxib The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Tolterodine.
Thalidomide Thalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Ibandronate.
Aluminum Hydroxide Aluminum Hydroxide The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.
Balsalazide Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Ibandronate.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibandronate.
Rabeprazole Rabeprazole The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.
Terbinafine Terbinafine The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists